CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

(MedPage Today) -- Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according to a retrospective study...

CD4+ T Cells Mediate CAR-T Cell-Associated Immune-Related Adverse Events after BCMA CAR-T Cell Therapy

Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel, 27 developed CAR T cell therapy-associated immune-related adverse events (CirAEs). This included one remarkable case with three distinct CirAEs in association with an extreme CD4+ CAR T cell expansion. [Nature Medicine] Abstract